Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Belite Bio, IncBelite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesBelite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia.
- LifeVantage CorporationLifeVantage Declares Quarterly DividendLifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.050 per share of common stock, which will be paid September 15, 2026 to all stockholders of record at the close of business on September 1, 2026.
- Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)
- Synergy CHC Corp. Announces Receipt of Nasdaq LetterSynergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, today announced that it received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) on August 20, 2026, indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Q2 Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). The Listing Rule requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC.
- Gossamer Bio, Inc.Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA ApprovalSAN DIEGO, August 21, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing e
- Decades of Clinical Excellence: Why Dr. Manju Aggarwal is a Leading Name in Indian NephrologyDr. Manju Aggarwal is a skilled nephrologist in Gurgaon, offering comprehensive kidney care, dialysis-related consultations, hypertension management, and specialized treatment for various kidney-related diseases and complex conditions.
- Hofseth BioCare ASA: SECOND QUARTER 2026 FINANCIAL REPORTHBC recorded total operating revenues of NOK 65.7 million in the second quarter of 2026, compared to NOK 68.4 million in the same period last year. Net operating revenues were NOK 63.1 million, down from NOK 67.8 million in Q2 2025. EBITDA for the quarter was negative NOK 2.7 million, compared to negative NOK 5.4 million in Q2 2025. The Operational EBITDA* amounted to negative NOK 0.6 million (positive NOK 1.3 million in Q2 2025), excluding non-recurring and strategic development costs such as clinical trials and R&D expenses, and Berkåk project costs. The operating result (EBIT) was negative NOK 12.9 (-14.9) in the last quarter. Cash and cash equivalents increased by NOK 59.7 million during the quarter, ending at NOK 108.0 million as of 30 June 2026 (68.0). Including available credit facilities, total liquidity was NOK 109.0 million at quarter-end (76.5).
- Akeso, Inc.Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its PipelineAkeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of...
- Implantica receives FDA approval for RefluxStop® - Opening the U.S. marketImplantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop®, the...
- Nebraska Orthopaedic Center Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal and Health InformationEdelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the Nebraska Orthopaedic Center data breach.
- Aveanna Announces Pricing of Secondary Offering of Common StockAveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today the pricing of the previously announced secondary offering by certain selling stockholders (the “Selling Stockholders”), including affiliates of J.H. Whitney Equity Partners VII, LLC and certain current and former directors and officers of the Company, of 15,000,000 shares of its common stock at a price of $11.75 per share (the “Offering”). Certain affiliates of J.H. Whitney Equity Partners VII, LLC have also granted the underwriter a 30-day option to purchase up to an additional 2,250,000 shares of the Company’s common stock. The Selling Stockholders will receive all of the net proceeds from the Offering. The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholders. The Offering is expected to settle on August 24, 2026, subject to customary closing conditions.
- Brii Biosciences LimitedBrii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial ResultsTopline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution...